|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.17 USD | -0.84% |
|
-3.32% | -1.57% |
| Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
| Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
Haemonetics Corporation Provided Earnings Guidance for the fiscal year 2022. Total company GAAP revenue guidance includes $90 to $95 million revenue related to Vascular Closure. Hospital organic revenue guidance includes a Hemostasis Management organic revenue growth in the mid-twenties.
Organic total revenue expected to be in the range of 5% to 7%.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.57% | 4.31B | |
| -0.78% | 189B | |
| -3.80% | 107B | |
| -5.26% | 67.81B | |
| +10.02% | 51.87B | |
| +16.01% | 46.67B | |
| -0.77% | 38.68B | |
| +7.77% | 27.73B | |
| +1.26% | 26.6B | |
| +5.43% | 26.34B |
HAEMONETICS CORPORATION 
